|
1
|
Secker-Walker LM, Craig JM, Hawkins JM and Hoffbrand AV: Philadelphia positive acute lymphoblastic leukemia in adults: Age distribution, BCR breakpoint and prognostic significance. Leukemia. 5:196–199. 1991.PubMed/NCBI
|
|
2
|
Burmeister T, Schwartz S, Bartram CR, Gökbuget N, Hoelzer D and Thiel E; GMALL study group, : Patients' age and BCR-ABL frequency in adult B-precursor ALL: A retrospective analysis from the GMALL study group. Blood. 112:918–919. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Preti HA, O'Brien S, Giralt S, Beran M, Pierce S and Kantarjian HM: Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients. Am J Med. 97:60–65. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, et al: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood. 100:2357–2366. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, et al: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood. 108:1469–1477. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, et al: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan adult leukemia study group. J Clin Oncol. 24:460–466. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, et al: Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy leukemia group protocol 09/00. J Clin Oncol. 28:3644–3652. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC, Escoffre M, Huguet F, Réa D, Delannoy A, et al: Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: A GRAALL study. Biol Blood Marrow Transplant. 19:150–155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, et al: UKALLXII/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 123:843–850. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, et al: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: Results of the gruppo italiano malattie ematologiche dell'adulto (GIMEMA) LAL0201-B protocol. Blood. 109:3676–3678. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, et al: First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 116:2070–2077. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, et al: Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 118:6521–6528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Groarke JD, Cheng S and Moslehi J: Cancer-drug discovery and cardiovascular surveillance. N Engl J Med. 369:1779–1781. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, et al: Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 125:2128–2137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, et al: Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 126:3207–3218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, et al: European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 30:1648–1671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
For R, Vitale A, Guarini A, De Propris MS, Elia L, Cimino G, Luppi M, Castagnola C, Sica S, Nieddu R, et al: Line treatment of adult ph+ acute lymphoblastic leukemia (ALL) patients: Final results of the GIMEMA LAL1205 study. Blood. 112:3052008. View Article : Google Scholar
|
|
18
|
Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, et al: Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 128:774–782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, et al: Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA. 103:7444–7449. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, et al: BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 473:384–388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trino S, Iacobucci I, Erriquez D, Laurenzana I, De Luca L, Ferrari A, Ghelli Luserna Di Rorà A, Papayannidis C, Derenzini E, Simonetti G, et al: Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. Oncotarget. 7:12951–12961. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jang SI, Jeong SI, Kim KJ, Kim HJ, Yu HH, Park R, Kim HM and You YO: Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells. Planta Med. 69:1057–1059. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsai MY, Yang RC, Wu HT, Pang JH and Huang ST: Anti-angiogenic effect of tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells. Cancer Lett. 310:198–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding L, Wang S, Wang W, Lv P, Zhao D, Chen F, Meng T, Dong L and Qi L: Tanshinone IIA affects autophagy and apoptosis of glioma cells by inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway. Pharmacology. 99:188–195. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Munagala R, Aqil F, Jeyabalan J and Gupta RC: Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer. Cancer Lett. 356:536–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Su CC and Chiu TL: Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. Oncol Rep. 36:1173–1179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, et al: Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA. 105:4826–4831. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shan YF, Shen X, Xie YK, Chen JC, Shi HQ, Yu ZP, Song QT, Zhou MT and Zhang QY: Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacol Sin. 30:1537–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu T, Zhou Z, Mu Y, de Lima Lopes G and Luo KQ: A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor. Cancer Lett. 346:94–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Zhang S and Chen X: Tanshinone IIA protects against cardiac fibrosis through inhibition of β-tubulin expression. J Biol Regul Homeost Agents. 32:1451–1455. 2018.PubMed/NCBI
|
|
31
|
Yu ML, Li SM, Gao X, Li JG, Xu H and Chen KJ: Sodium tanshinone II A sulfonate for coronary heart disease: A systematic review of randomized controlled trials. Chin J Integr Med. 26:219–226. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meng ZJ, Wang C, Meng LT, Bao BH, Wu JH and Hu YQ: Sodium tanshinone IIA sulfonate attenuates cardiac dysfunction and improves survival of rats with cecal ligation and puncture-induced sepsis. Chin J Nat Med. 16:846–855. 2018.PubMed/NCBI
|
|
33
|
He Z, Sun C, Xu Y and Cheng D: Reduction of atrial fibrillation by tanshinone IIA in chronic heart failure. Biomed Pharmacother. 84:1760–1767. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo Y, Li Y, Xiang B, Huang XO, Ma HB, Wang FF and Gong YP: Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL. Biochem J. 474:4153–4170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Khoo KH, Verma CS and Lane DP: Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat Rev Drug Discov. 13:217–236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo R, Li L, Su J, Li S, Duncan SE, Liu Z and Fan G: Pharmacological activity and mechanism of tanshinone IIA in related diseases. Drug Des Devel Ther Nov. 14:4735–4748. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mayo LD and Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA. 98:11598–11603. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Giaccia AJ and Kastan MB: The complexity of p53 modulation: Emerging patterns from divergent signal. Genes Dev. 12:2973–2983. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cory S and Adams JM: The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer. 2:647–656. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A and Neubauer A: Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia. 19:1774–1782. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Quentmeier H1, Eberth S, Romani J, Zaborski M and Drexler HG: BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 4:62011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Moll UM and Petrenko O: The MDM2-p53 interaction. Mol Cancer Res. 1:1001–1008. 2003.PubMed/NCBI
|
